je.st
news
Tag: merck
Merck to Acquire Idenix
2014-06-09 13:30:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. & CAMBRIDGE, Mass. Acquisition Expands Portfolio of Promising Investigational Therapies for Hepatitis C WHITEHOUSE STATION, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), today announced that the companies have entered into a definitive agreement under which Merck will acquire Idenix for $24.50 per share in cash. The transaction, which values the purchase of Idenix at approximately $3.85 billion, has been approved by the boards of directors of both companies. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Steve Cragle, 908-423-3461orInvestors:Joe Romanelli, 908-423-5185Justin Holko, 908-423-5088orIdenixMedia/Investors:Teri Dahlman, 617-995-9807 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Merck to Present New Clinical Data on JANUVIA (Sitagliptin), Investigational Omarigliptin, and Real-World Data in Patients with Type 2 Diabetes at the 74th Scientific Sessions of the American Diabetes Association
2014-06-06 14:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, will present 13 new studies and analyses, including data for its DPP-4 inhibitor JANUVIA (sitagliptin) and for its investigational once-weekly DPP-4 inhibitor omarigliptin, at the 74th Scientific Sessions of the American Diabetes Association (ADA) being held in San Francisco, June 13-17, 2014. Several analyses of patient data in real-world settings will also be presented. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orKim Hamilton908-423-6831 or 908-391-0131orInvestor:Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Novartis appoints Merck executive as oncology chief
2014-06-02 10:25:02| Biotech - Topix.net
Swiss drugmaker Novartis AG said it has appointed Bruno Strigini, one of Merck & Co Inc's top executives, to head its oncology unit.
Tags: executive
chief
oncology
merck
Merck Announces Third-Quarter 2014 Dividend
2014-05-27 18:21:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.44 per share of the companys common stock for the third quarter of 2014. Payment will be made on July 8, 2014, to stockholders of record at the close of business on June 16, 2014. About Merck Language: English Contact: MerckMedia:Lainie Keller, 908-423-4187orInvestors:Carol Ferguson, 908-423-4465 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: announces
dividend
merck
announces thirdquarter
Is Merck Poised to Head Higher?
2014-05-25 10:55:42| Biotech - Topix.net
The company consists of four operating segments: the Pharmaceutical, Animal Health, Consumer Care, and Alliances segments, and one reportable segment in the Pharmaceutical segment.
Tags: head
higher
poised
merck
Sites : [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] next »